EZH2 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, research has revealed that reprogramming of enhancer of zeste homolog 2 (EZH2) and H3K27me3 is crucial for CML-LSCs survival, suggesting a combined treatment approach with EZH2i and TKIs could improve therapeutic efficacy [32].